PPBT (Purple Biotech) ROCE %: -2.36% (As of Mar. 2026)


PPBT Purple Biotech Ltd PPBT
25 GF Score
Price $1.72
! 2 Warning Signs
View Full Analysis

What is Purple Biotech ROCE %?

Purple Biotech PPBT +2.38% 25 ROCE % is -2.36% as of Mar. 2026. GuruFocus rates PPBT with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Purple Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was -2.36%.

Purple Biotech  (NAS:PPBT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Purple Biotech ROCE % Related Terms

Purple Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Purple Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech ROCE % Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.20 -38.22 -48.49 -21.40 -123.41

Purple Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.11 -13.40 -15.95 -441.24 -2.36
PPBT
25GF Score
Purple Biotech Ltd PPBT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech ROCE % Calculation

Purple Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-26.453/( ( (37.038 - 3.987) + (17.572 - 7.753) )/ 2 )
=-26.453/( (33.051+9.819)/ 2 )
=-26.453/21.435
=-123.41 %

Purple Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-0.232/( ( (17.572 - 7.753) + (14.417 - 4.593) )/ 2 )
=-0.232/( ( 9.819 + 9.824 )/ 2 )
=-0.232/9.8215
=-2.36 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -2.36% mean?
Purple Biotech (PPBT) has a ROCE % of -2.36% as of Mar. 2026.
Is Purple Biotech's ROCE % too high?
Purple Biotech's current ROCE % is -2.36%. Overall, Purple Biotech has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's ROCE % compare to VRTX and REGN?
Purple Biotech's ROCE % of -2.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Purple Biotech's current ROCE % is -2.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current ROCE % of -2.36%. The current ROCE % is -2.36%. Purple Biotech's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Purple Biotech (PPBT), the current ROCE % is -2.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
25GF Score

Get the complete analysis for PPBT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price